These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 13076081)

  • 1. [Experimental research on the anticoagulant marcoumar (3-(1-phenyl-propyl)-4-hydroxy-coumarin) and its antagonist konakion (synthetic vitamin K1)].
    JURGENS R
    Schweiz Med Wochenschr; 1953 May; 83(20):471-5. PubMed ID: 13076081
    [No Abstract]   [Full Text] [Related]  

  • 2. [Intravenous administration of marcoumar].
    DEUTSCH E
    Wien Klin Wochenschr; 1956 Jul; 68(27):553-5. PubMed ID: 13353090
    [No Abstract]   [Full Text] [Related]  

  • 3. Studies on the efficiency of vitamin K1 in small doses as antidote against anticoagulants of the dicoumarol type.
    GEILL T; LUND E; DAM H; SØNDERGAARD E
    Scand J Clin Lab Invest; 1954; 6(3):203-9. PubMed ID: 13205146
    [No Abstract]   [Full Text] [Related]  

  • 4. [Tromexan and marcoumar in anticoagulant therapy; micromethod for determination of prothrombin-proconvertin activity].
    IVERSEN T
    Ugeskr Laeger; 1955 Jul; 117(27):873-8. PubMed ID: 13256759
    [No Abstract]   [Full Text] [Related]  

  • 5. Anticoagulant studies with marcoumar, a new coumarin derivative.
    PRIOR IA
    Br Med J; 1955 Oct; 2(4945):944-6. PubMed ID: 13260634
    [No Abstract]   [Full Text] [Related]  

  • 6. A new highly active anticoagulant with prolonged effect (marcoumar).
    KOLLER F; JAKOB H
    Schweiz Med Wochenschr; 1953 May; 83(20):476-9. PubMed ID: 13076082
    [No Abstract]   [Full Text] [Related]  

  • 7. Anticoagulant therapy with tromexan and marcoumar and determination of the prothrombin-proconvertin activity by a micro-method.
    IVERSEN T
    Acta Med Scand; 1956 Sep; 155(3):161-70. PubMed ID: 13361829
    [No Abstract]   [Full Text] [Related]  

  • 8. Synthesis of 3-amino-4-hydroxy coumarin and dihydroxy-phenyl coumarins as novel anticoagulants.
    Danis O; Yuce-Dursun B; Gunduz C; Ogan A; Sener G; Bulut M; Yarat A
    Arzneimittelforschung; 2010; 60(10):617-20. PubMed ID: 21125812
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Clinical studies on the new anticoagulant, marcoumar, and its antagonist, konakion (vitamin K1)].
    GAGLIARDI L
    Gynaecologia; 1954 Sep; 138(3):424-40. PubMed ID: 13210728
    [No Abstract]   [Full Text] [Related]  

  • 10. Clinical experience with coumarin anticoagulants warfarin and warfarin sodium.
    CLATANOFF DV; TRIGGS PO; MEYER OO
    AMA Arch Intern Med; 1954 Aug; 94(2):213-20. PubMed ID: 13180041
    [No Abstract]   [Full Text] [Related]  

  • 11. [Behavior of hematic fibrinogen during treatment with marcoumar and with marcoumar and vitamin K; clinical and experimental aspects].
    RICCI M
    Arch Sci Med (Torino); 1955 Feb; 99(2):112-29. PubMed ID: 13259907
    [No Abstract]   [Full Text] [Related]  

  • 12. [Decrease of hemorrhagic accidents in anticoagulant therapy with coumarin derivatives by administration of vitamin K1].
    THEDERING F; BOWING G
    Munch Med Wochenschr; 1956 Mar; 98(10):340-4. PubMed ID: 13334377
    [No Abstract]   [Full Text] [Related]  

  • 13. [Clinical study of the anticoagulant 3-(1-phenylpropyl)-4-hydroxycoumarin or marcoumar and of its antidote, vitamin K1].
    GAGLIARDI L
    Minerva Ginecol; 1954 Jan; 6(2):84-97. PubMed ID: 13154044
    [No Abstract]   [Full Text] [Related]  

  • 14. [The control of dangerous effects of coumarin with vitamin K1 (konakion)].
    THIES HA
    Medizinische; 1955 Oct; (40):1411-5. PubMed ID: 13272564
    [No Abstract]   [Full Text] [Related]  

  • 15. Effect of oral anticoagulant (marcumar) on prothrombin and related components in blood coagulation.
    JOHNSON SA; CALDWELL MJ; PRIEST EM
    Circ Res; 1957 May; 5(3):252-6. PubMed ID: 13427137
    [No Abstract]   [Full Text] [Related]  

  • 16. [Variations in fibrinogenemia, prothrombin time and liquoid coagulation time during treatment with anticoagulants].
    FRANCESCON M; BUTTO M
    Acta Med Patav; 1952; 13(6):265-88. PubMed ID: 13039951
    [No Abstract]   [Full Text] [Related]  

  • 17. [Control of dicoumarin effect on blood coagulation].
    THIES HA
    Langenbecks Arch Klin Chir Ver Dtsch Z Chir; 1952-1953; 273():320-2. PubMed ID: 13045631
    [No Abstract]   [Full Text] [Related]  

  • 18. STUDIES ON THE COUMARIN ANTICOAGULANT DRUGS: THE PHARMACODYNAMICS OF WARFARIN IN MAN.
    O'REILLY RA; AGGELER PM; LEONG LS
    J Clin Invest; 1963 Oct; 42(10):1542-51. PubMed ID: 14074349
    [No Abstract]   [Full Text] [Related]  

  • 19. [Protective action of vitamin E on lesions caused by marcoumar].
    SALVI F; MENTASTI P
    Acta Vitaminol; 1956 Feb; 10(1):17-26. PubMed ID: 13313283
    [No Abstract]   [Full Text] [Related]  

  • 20. [Phenylpropyl hydroxycoumarin as anticoagulant in obstetric and gynecological thrombophlebitis and its antidote, vitamin K1].
    DE DOMINICIS E; ROLANDI L
    Riv Ostet Ginecol Prat; 1955 Nov; 37(11):658-65. PubMed ID: 13281402
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.